Technical Data
D1075-01P
DARPP32 (Dopamine and cAMP-regulated Phosphoprotein DARPP32, DARPP 32, DARPP-32, Dopamine- and cAMP-regulated Neuronal Phosphoprotein, Protein Phosphatase 1 Regulatory Subunit 1B, Ppp1r1b)
Description:
DARPP-32 is a dopamine (DA) and cAMP-regulated ~32kD phosphoprotein that is associated with dopaminoceptive neurons (Fienberg et al., 1998). The protein inhibits Protein Phosphatase I when it is phosphorylated on Thr34. In contrast, when DARPP-32 is phosphorylated on Thr75 the protein acts as an inhibitor of PKA (Bibb et al., 1999). Phosphorylation of DARPP-32 is thought to play a critical role in the regulation of dopaminergic neurotransmission. In addition, the activity of DARPP-32 is also thought to play important roles in the actions of alcohol, caffeine and ProzacŪ (Maldve et al., 2002; Lindskog et al., 2002; Svenningsson et al., 2002).

Applications:
Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000
Optimal dilutions to be determined by the researcher.

Positive Control:
Rat hippocampal lysate

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
100ul-20°CBlue IceRatRabbit
Concentration:
Not determined
Immunogen:
Peptide corresponding to amino acid residues from the N-terminal region of rat DARPP-32 (KLH).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in 1 mM HEPES, pH 7.5, 150mM sodium chloride, 100ug per ml BSA, 50% glycerol.
Specificity:
Recognizes rat DARPP-32. Species sequence homology: human.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC, Jr., Nairn AC, Greengard P (1999) Phosphorylation of DARPP-32 by cdk5 modulates dopamine signalling in neurons. Nature (London) 402:669-671. 2. Fienberg, A.A., Hiroi, N., Mermelstein, P.G., Song, W., Snyder, G.L., Nishi, A., Cheramy, A. O'Callaghan, J.P., Miller, D.B., Cole, D.G., Corbett, R., Haile, C.N., Cooper, D,C., Onn, S.P., Grace, A.A., Ouimet, C.C., White, F.G., Hyman, S.E., Surmeier, D.G., Girault, J., Nestler, E.J. and Greengard, P. (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281:838-842. 3. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G (2002) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (London) 418:774-778. 4. Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, Feinberg AA, Leslie SW, Gonzales RA, Morrisett RA (2002) DARPP-32 and the regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbens. Nature Neurosci 5:641-648. 5. Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P (2002) Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (ProzacŪ). Proc Natl Acad Sci USA 99:3182-3187.